Abstract Background: Genomic markers such as ESR1, PGR, EGFR, MKI67, and FOXC1, along with clinically validated multigene signatures like Oncotype DX, MammaPrint, Prosigna, and EndoPredict, are widely used to inform prognosis and guide therapeutic decisions in breast cancer. However, the widespread use of these gene expression-based assays is often constrained by their high cost and limited accessibility. To address this challenge, we developed an AI model capable of inferring the spatial distribution of gene expression directly from routine digitized H 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD11-05.
Chavan et al. (Tue,) studied this question.